Variable	Age	Sex	Underlying disease	Previous lines of therapy	Immunomodulatory agents	Pre-trasplant response	Previous radiotherapy	Conditioning regimen	G-CSF
n	<65(101) >65(33) Median (57) Range (18-73)	Male(74) Female(60)	MM(86) NHL(25) HL(8) AM(3) AD(6) ST(5) AML(1)	One(78) Two(42) Three(8) Four(3) Five(1) Seven(1) Nine(1)	YES(85) NO(49)	Complete response(79) Partial response(48) Refractory(6) Relapse(1)	YES(15) NO(119)	Melphalan (83) BEAM (29) BUMEL(7) Cyclophosphamide+ATG(6) Carmustine+Thiotepa(4) Carboplatin+Etoposide(4) BEA(1)	YES(50) NO(84)
%	<65(75,4) >65(24,6)	Male(55,2) Female(44,8)	MM(64,2) NHL(18,7) HL(6) AM(2,2) AD(4,4) ST(3,8) AML(0,7)	One(58,3) Two(31,4) Three(6) Four(2,2) Five(0,7) Seven(0,7) Nine(0,7)	YES(63,4) NO(36,6)	Complete response(59) Partial response(35,9) Refractory(4,4) Relapse(0,7)	YES(11,2) NO(88,8)	Melphalan(62) BEAM(21,6) BUMEL(5,3) Cyclophosphamide+ATG(4,4) Carmustine+Thiotepa(3) Carboplatin+Etoposide(3) BEA(0,7)	YES(37,3) NO(62,7)

[TABLE1 MM:Multiple myeloma NHL:Non-Hodgkin lymphoma HL:Hodgkin lymphoma AM:Amyloidosis AD:Autoimmune disease ST:Solid tumor AML:Acute myeloid leukemia]